Senores Pharmaceuticals Q1 FY26 Results: PAT…

12 hrs ago

Doubling FY26 PAT with 50% growth in revenue. Potential to deliver 20-30% revenue CAGR in FY27. At reasonable forward valuations with leeway for execution risks

Read →

Comments

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts

Money Muscle

Senores Pharmaceuticals Q1 FY26 Results: PAT…